Published results of the clinical evaluation of various short courses with both metronidazole (Csonka, 1971; Woodcock, 1972,;  Morton, 1972; Ross, 1973b; Davidson, 1973) and nimorazole (Jelinek and Jones, 1971; McCann and others, 1972; Campbell, 1972; Jones, 1972; Ross, 1973a,b) confirn that shortened courses are as efficacious as standard courses. With nimorazole in particular, a dosage of 1 g. at 12-hrly intervals for three doses, over a period of 24 hrs, gave highly satisfactory results (97*1 per cent. cure rate) with very rare side-effects (Campbell, 1972) . Only one of the above published trials (Ross, 1973b) compared the two drugs.
Received for publication May 10, 1975 It was decided to evaluate nimorazole in the '24-hr' treatment of vaginal trichomoniasis administering 3 g. (two 500 mg. tablets 12-hrly for three doses), and to compare the results with those obtained with metronidazole using the manufacturer's standard dosage of 4-2 g. (one 200 mg. tablet three times daily for 7 consecutive days).
Patients
The trial took place between June 1, 1972, and June 18, 1973 , and included patients with trichomonal vaginitis diagnosed by positive darkground microscopy showing motile trichomonads. Excluded from the trial were patients known to be pregnant or who reported an overdue menstrual period. 99 persons (100 cases) were treated with metronidazole, one patient becoming re-infected and being re-treated on the same schedule. 100 persons were treated with nimorazole. At first the patients were advised to ask their consorts to attend for examination and therapeutic or epidemiological treatment. After the first fifty cases in each schedule had been recorded, the practice of asking consorts to attend was discontinued as being unproductive.
Methods
The two treatment schedules were given to alternate patients. Treatment was commenced upon diagnosis except that the patients taking nimorazole were told to time their three doses so that they were taken at precisely 12-hr intervals without the necessity for waking up at night. Thus, patients diagnosed in the afternoon delayed their first dose until the evening. All patients were instructed to take their tablets after meals and to avoid both alcohol and sexual intercourse. Patients found to have concomitant gonorrhoea were treated with a combination of probenecid, penicillin, and cotrimoxazole; patients with vaginal candidiasis were treated with amphotericin B vaginal pessaries and oral tablets. All patients were asked to return on completion of treatment and thereafter at weekly intervals for three further tests including one after their next menstrual period, which in many cases occurred after their third attendance but which in some occurred earlier than this. At follow-up attendances all patients were group.bmj.com on July 6, 2017 -Published by http://sti.bmj.com/ Downloaded from Trichononal vaginitis 55 examined clinically and specimens of the vaginal secretions were subjected to microscopy and culture using FeinbergWhittington medium. To assess the efficacy of the latter, material from 22 Trichomonas-positive patients was cultured before treatment and all these cultures were likewise positive.
Results
The Table shows Although the official follow-up ceased after the fourth test and did not extend to a 3-month surveillance, no case, other than the one recorded, returned within the following 2 months with a fresh trichomonal vaginitis.
Discussion
The number of cases involved in this trial is rather small for statistical conviction concerning the results but confidence can be placed in both forms of treatment. The way seems open for considerable shortening of routine treatment which may yet contract down to a single 'once-for-all' dosage. This could lead to trichomonal vaginitis being the first sexually-transmissible disease to be treated out of existence.
Provided concomitant infections are appropriately treated, their presence appears to have no adverse effect on the treatment for trichomoniasis, but their very existence in over half the cases deserves close attention.
A 100 per cent. success rate calls for some comment, for such cannot be lightly claimed without engendering doubt or scepticism. Both metronidazole and nimorazole are very effective drugs and the reasons why no clinical trial had previously produced the theoretically possible cure rate of 100 per cent, are the probable inclusion among patients of the inevitable 'tablet defaulter' and the possible inclusion of patients in whom absorption was defective or in whom metabolism of the drugs into inactive products occurred before they reached the vagina. According to Cohen (1971) , the incidence of patients not responding to trichomonicidal drugs in his clinic in 10 years has been about 1 in 150.
Cure rates near to 100 per cent. have been reported with both drugs. With metronidazole, Keighley (1971) reported 98 per cent. and Davidson (1973) 98 6 per cent. success. With nimorazole, Cohen (1971) reported 98 per cent., Ross (1973a) 96 per cent., and Campbell (1972) 
